Press Releases Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 15:17:35 15/01/2026 GMT			5-day change	1st Jan Change
368.44 ^USD	+0.43%		-7.00%	-6.59%

01-14	Alnylam Pharmaceuticals Insider Sold Shares Worth $1,395,992, According to a Recent SEC Filing	MT
01-14	Alnylam Pharmaceuticals Insider Sold Shares Worth $547,927, According to a Recent SEC Filing	MT

Press Releases

01-12	Alnylam Pharmaceuticals : 2026 J.P. Morgan Presentation	PU
01-11	Alnylam Pharmaceuticals : Launches “ 2030” Strategy to Drive Next Era of Growth and Patient Impact	PU
01-11	Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact	BU
01-05	Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference	BU
12-17	Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics	BU
12-11	Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027	BU
12-03	Alnylam Pharmaceuticals Announces Changes to Board of Directors	BU
11-08	New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM	BU
11-04	Alnylam to Webcast Presentations at Upcoming November Investor Conferences	BU
30/10/25	Alnylam Pharmaceuticals : Q3 2025 Earnings Presentation	PU
30/10/25	Alnylam Pharmaceuticals : Q3 2025 GAAP/Non-GAAP Reconciliation ›	PU
30/10/25	Alnylam: Q3 Earnings Snapshot	AQ
30/10/25	Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress	BU
16/10/25	Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results	BU
01/10/25	Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran	BU
29/09/25	Alnylam Pharmaceuticals, Inc. - New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran	AQ
28/09/25	New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran	BU
18/09/25	Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine	PR
10/09/25	Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes	BU
09/09/25	Alnylam Pharmaceuticals Announces Proposed Offering of $500 Million Convertible Senior Notes	AQ
08/09/25	Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes	BU
01/09/25	Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial	AQ
01/09/25	Genentech and Alnylam Advance Zilebesiran into Global Phase III Cardiovascular Outcomes Trial for People with Uncontrolled Hypertension	AQ
01/09/25	Alnylam Pharmaceuticals - New Data from Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM	AQ
01/09/25	Roche touts 'best-in-disease' potential for anti-hypertensive zilebesiran	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Alnylam Pharmaceuticals CEO on Development Goals, Profitability

January 13, 2026 at 10:11 am